---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-049935"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2022-04-26T23:59:59+00:00"
generated_at: "2026-06-26T04:34:34.947949+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharma appoints Susan L. Drexler as Interim CFO effective Apr 21, 2022

## Summary
- Susan L. Drexler appointed Interim CFO, principal accounting officer and principal financial officer effective April 21, 2022.
- Over 25 years of life science CFO experience; previously CFO of Harmony Biosciences (HRMY) and roles at Ocugen, Shire.
- Services provided via Danforth Advisors consulting agreement at $450/hour; termination requires 30 days (with cause) or 60 days (without cause) notice.
- No family relationship or reportable transactions between Drexler and any Kiora director or executive officer.

## SEC filing metadata
- accession: 0001104659-22-049935
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2022-04-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000110465922049935/0001104659-22-049935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000110465922049935/tm2213276d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-049935
- JSON: https://secwatch.observer/filing/0001104659-22-049935.json
- Plain text: https://secwatch.observer/filing/0001104659-22-049935.txt

## Key facts
- Executive change
  Susan L. Drexler was appointed as Interim Chief Financial Officer at KIORA PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: On April 21, 2022 (the “Effective Date”), the Board of Directors of Kiora Pharmaceuticals Inc. (the “Company”) appointed Susan L. Drexler as Interim Chief Financial Officer of the Company, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000110465922049935/0001104659-22-049935-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.